Abstract
Aims: To evaluate the efficacy and safety of celecoxib in patients with osteoarthritis who previously failed naproxen and ibuprofen treatment. Materials & methods: Two identical, 6-week, randomized, double-blind, placebo-controlled trials of celecoxib 200 mg daily were undertaken in patients with knee osteoarthritis. The primary efficacy variable was the 6-week change in Patient's Assessment of Arthritis Pain visual analog scale. Results: In study 1 (n = 370), the visual analog scale least squares mean decrease from baseline was 27.3 (celecoxib) versus 14.9 mm (placebo; p < 0.001); it was 28.0 versus 24.6 mm, respectively, in study 2 (n = 380). Conclusion: Celecoxib was well tolerated, yet the efficacy results differed, highlighting the complexities of treating patients with osteoarthritis who have failed previous NSAID treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
